As of May 27, 2025, Oasmia Pharmaceutical AB (OASM.ST) reports a EV/EBITDA of -8.80.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Oasmia Pharmaceutical AB's EV/EBITDA to Peers
To better understand Oasmia Pharmaceutical AB's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Oasmia Pharmaceutical AB (OASM.ST) | -8.80 |
| Bonesupport Holding AB (BONEX.ST) | 100.47 |
| Probi AB (PROB.ST) | 35.44 |
| Synthaverse SA (BML.WA) | 20.56 |
| Vitrolife AB (VITR.ST) | 20.35 |
| Biogaia AB (BIOG B.ST) | 19.35 |
Compared to its competitors, Oasmia Pharmaceutical AB's EV/EBITDA is among the lowest compared to peers, which may indicate undervaluation or market concerns about future performance.